The effect of quinidine, used as a probe for the involvement of P-glycoprotein, on the intestinal absorption and pharmacodynamics of methadone.
about
P-glycoprotein is a major determinant of norbuprenorphine brain exposure and antinociceptionFunctional impact of ABCB1 variants on interactions between P-glycoprotein and methadoneEvaluating the safety and efficacy of dextromethorphan/quinidine in the treatment of pseudobulbar affectPharmacokinetics of methadone.Effects of HM30181, a P-glycoprotein inhibitor, on the pharmacokinetics and pharmacodynamics of loperamide in healthy volunteers.Ethnic and genetic factors in methadone pharmacokinetics: a population pharmacokinetic studyMethadone dose in heroin-dependent patients: role of clinical factors, comedications, genetic polymorphisms and enzyme activityCyclosporine-inhibitable cerebral drug transport does not influence clinical methadone pharmacodynamics.Solid-phase microextraction of methadone in urine samples by electrochemically co-deposited sol-gel/Cu nanocomposite fiber.Opioid analgesics-related pharmacokinetic drug interactions: from the perspectives of evidence based on randomized controlled trials and clinical risk managementMechanism of ritonavir changes in methadone pharmacokinetics and pharmacodynamics: I. Evidence against CYP3A mediation of methadone clearance.Pharmacokinetic interactions between buprenorphine and antiretroviral medications.Pharmacogenetics of opioids.Interindividual variability of methadone response: impact of genetic polymorphism.Mitochondrial Dysfunction in Gliomas: Pharmacotherapeutic Potential of Natural Compounds.Pharmacogenetics of analgesics: toward the individualization of prescription.Methadone: a review of drug-drug and pathophysiological interactions.Metabolic and toxicological considerations of the opioid replacement therapy and analgesic drugs: methadone and buprenorphine.Pharmacogenomics of methadone maintenance treatment.Association Between Human Pain-Related Genotypes and Variability in Opioid Analgesia: An Updated Review.Relevance of P-glycoprotein in stroke prevention with dabigatran, rivaroxaban, and apixaban.Opioids and the blood-brain barrier: a dynamic interaction with consequences on drug disposition in brain.Opioids Resistance in Chronic Pain Management.Interaction of drugs of abuse and maintenance treatments with human P-glycoprotein (ABCB1) and breast cancer resistance protein (ABCG2).Intraoperative methadone: rediscovery, reappraisal, and reinvigoration?St John's wort greatly reduces the concentrations of oral oxycodone.Very-high-dose methadone with minimal toxicity and inadequate pain control in a hospice patient with cancer.The effects of inhibiting cytochrome P450 3A, p-glycoprotein, and gastric acid secretion on the oral bioavailability of methadone in dogs.Role of CYP3A5 in abnormal clearance of methadone.Pharmacokinetic and pharmacodynamic study of the concomitant administration of methadone and TMC125 in HIV-negative volunteers.Current Concepts in Methadone Metabolism and Transport.
P2860
Q24631289-5E1B4C9B-5C74-47CC-819F-5AA0AA5BB3CBQ28488223-DB561EE1-58F8-43CF-9255-05CBC85C3B9CQ33838839-424BF4AC-B6F8-44CE-9F22-90D3848DA2B5Q34487284-052773E2-CC28-4001-92C5-C833C7EDA987Q34571054-F883E31E-F700-4BF0-954F-F5D80197E633Q34626158-DE4C4F2E-8171-4AF9-9134-F16C5212A461Q35684822-4051A47E-5C37-4E2E-95AF-BFA4E2E4D16FQ36036200-9EB8AD58-7C0B-42C8-9540-FCA63E2816B8Q36236156-AC4D2C86-57D9-4C89-9608-282003282DA6Q36392325-6C7119A9-6095-44E3-BD13-00AD1DDE8987Q36641884-FDF2D64D-203B-467E-BBC7-C13728656241Q36655057-545ABD22-42B2-4356-B7BC-B45171962C39Q36752672-DEEEB377-C974-489F-8D6C-D31C4AB5FB9CQ37142009-171FD0B3-2E6A-4136-BB88-646B528E0E35Q37168749-372F72A4-1D33-4284-BBCD-F29D63855D20Q37205954-18AF81B4-98F9-45F8-BE5B-2DF7ED1CACFCQ37950478-7EED8735-FB6D-4142-A641-8EE69742DF13Q38093852-6D285239-06C8-487C-99EE-0B584E97357FQ38222510-A7B3C59B-BA93-4701-AD1A-6C0324753B0CQ38247246-D6988995-4DA7-44FD-AF54-AF08555E68A0Q38330349-9FBEAEF0-270B-4B1E-BE8A-BB5A336E2E38Q39285381-E6EC1B35-8981-4909-9328-102544171384Q39305721-5C7EED0D-B67B-4723-9A2B-647593452549Q39779618-BED4F909-EE6B-4FFF-A342-BFACBD372E08Q43119468-7E27A878-4078-4F55-AB6F-F0BB1E9FA675Q43182631-A69C4FAE-F9E2-471E-94F8-CB8CBE1CEB62Q44012678-9A0923C9-627C-45DE-86E9-09A3B457CF95Q44863552-FB06E91E-4141-4EF2-B2E9-A72D2A5609FAQ46609377-131ED516-5837-4170-9AB2-5FBFA30E4059Q46808283-B33A38F7-7558-444D-AE23-99D9A9763126Q50682107-8F090C36-B91A-45CD-94B8-39D11B2FB9AC
P2860
The effect of quinidine, used as a probe for the involvement of P-glycoprotein, on the intestinal absorption and pharmacodynamics of methadone.
description
2004 nî lūn-bûn
@nan
2004年の論文
@ja
2004年論文
@yue
2004年論文
@zh-hant
2004年論文
@zh-hk
2004年論文
@zh-mo
2004年論文
@zh-tw
2004年论文
@wuu
2004年论文
@zh
2004年论文
@zh-cn
name
The effect of quinidine, used ...... pharmacodynamics of methadone.
@ast
The effect of quinidine, used ...... pharmacodynamics of methadone.
@en
type
label
The effect of quinidine, used ...... pharmacodynamics of methadone.
@ast
The effect of quinidine, used ...... pharmacodynamics of methadone.
@en
prefLabel
The effect of quinidine, used ...... pharmacodynamics of methadone.
@ast
The effect of quinidine, used ...... pharmacodynamics of methadone.
@en
P2093
P2860
P1476
The effect of quinidine, used ...... pharmacodynamics of methadone.
@en
P2093
Christine Hoffer
Dale Whittington
Evan D Kharasch
P2860
P304
P356
10.1111/J.1365-2125.2003.02053.X
P407
P577
2004-05-01T00:00:00Z